一句话亮点

这项研究发现LY96蛋白在间充质（MES）型胶质母细胞瘤（GBM）中扮演了"双面间谍"：它既是MES型肿瘤干细胞（GSCs）通过自分泌环路维持自身干性和MES身份的"燃料"，又是通过旁分泌方式将肿瘤相关巨噬细胞（TAMs）改造成MES样促癌状态的"信号弹"。

背景/痛点

GBM是颅内最常见的原发恶性肿瘤，其中MES亚型预后最差，并且对现有治疗抵抗最顽固。以往的测序研究发现MES亚型肿瘤中巨噬细胞浸润特别多，肿瘤细胞和巨噬细胞都呈现出一种MES样的转录组特征。这提示两者之间可能存在双向的"对话"，但具体是谁先发出的信号、通过什么分子实现，一直不清楚。

LY96（也叫MD-2）以前被熟知的身份是TLR4受体复合物的共受体，在天然免疫识别细菌LPS中至关重要。但在GBM里，尤其是MES亚型里，它到底起什么作用？这恰恰是本文要解决的问题。

推理链分步拆解

Step 1：先锁定"嫌疑分子"——LY96凭什么值得看？

作者一开始的思路很直接：既然MES GBM最凶险，那一定是MES型肿瘤干细胞（GSCs）在搞鬼。他们想找到一个由MES GSCs高表达、能分泌出去、且跟患者不良预后挂钩的蛋白。

于是他们搞了一套多组学筛选：把TCGA的GBM肿瘤组织和正常脑组织做对比，同时联合GSC细胞系的蛋白质组数据和RNA测序数据，层层过滤。筛选条件包括：①在MES型肿瘤和MES GSCs中均高表达；②是分泌蛋白；③高表达与TCGA患者较差生存相关；④表达水平与MES特征评分正相关。

最后排在榜首的是LY96。@方法论点评：这是一个典型的"表型驱动+多组学锁靶"策略。好处是层层叠加，假阳性率低；代价是可能漏掉表达不那么"壮观"但功能重要的分子。

Fig. 1：MES GSC-specific LY96 secretion is associated with mesenchymal GBM microenvironment remodeling A, The UMAP plot of GBM samples annotated by major cell types in HRA004899 GBM scRNA-seq dataset (n = 7). B, Bar plots showing the distribution of transcriptional states among tumor cells in HRA004899 GBM scRNA-seq dataset (n = 7). C, Violin plots comparing MES signature scores in TAMs from GBM tumors with high versus low MES tumor cell content in HRA004899 GBM scRNA-seq dataset (n = 7). D, Schematic of the multi-omics screening workflow used to identify key secreted proteins enriched in MES GSCs. E, Correlation between LY96 expression and MES signature scores across GBM transcriptomic datasets. F, Bubble plot showing normalized LY96 expression across tumor cell states identified in GBM single-cell RNA-seq data. G–H, Quantitative RT-PCR analysis of LY96 mRNA levels in GBM vs. normal brain tissues (G) and in NSCs vs. GSCs (H). Data are shown as mean ± SD and analyzed by unpaired t-test. P < 0.05, P < 0.01. I–J, Immunoblot analysis of LY96 protein levels in GBM vs. normal brain tissue (I) and in NSCs vs. GSCs (J). K, Immunofluorescent staining(left) of LY96 (green) and CD44 (red) in MES GSCs (839, 2907) and non-MES GSCs (3094, RKI). And quantification of the intensity of immunofluorescence signals of LY96(right).Scale bar, 50 μm L, Immunofluorescence of GBM patient specimens showing LY96+ cells within the SOX2+ tumor cell population. Scale bar, 10 μm. (For interpretation of the ref\u00ad erences to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 1. MES GSC-specific LY96 secretion is associated with mesenchymal GBM microenvironment remodeling A, The UMAP plot of GBM samples annotated by major cell types in HRA004899 GBM scRNA-seq dataset (n = 7). B, Bar plots showing the distribution of transcriptional states among tumor cells in HRA004899 GBM scRNA-seq dataset (n = 7). C, Violin plots comparing MES signature scores in TAMs from GBM tumors with high versus low MES tumor cell content in HRA004899 GBM scRNA-seq dataset (n = 7). D, Schematic of the multi-omics screening workflow used to identify key secreted proteins enriched in MES GSCs. E, Correlation between LY96 expression and MES signature scores across GBM transcriptomic datasets. F, Bubble plot showing normalized LY96 expression across tumor cell states identified in GBM single-cell RNA-seq data. G–H, Quantitative RT-PCR analysis of LY96 mRNA levels in GBM vs. normal brain tissues (G) and in NSCs vs. GSCs (H). Data are shown as mean ± SD and analyzed by unpaired t-test. P < 0.05, P < 0.01. I–J, Immunoblot analysis of LY96 protein levels in GBM vs. normal brain tissue (I) and in NSCs vs. GSCs (J). K, Immunofluorescent staining(left) of LY96 (green) and CD44 (red) in MES GSCs (839, 2907) and non-MES GSCs (3094, RKI). And quantification of the intensity of immunofluorescence signals of LY96(right).Scale bar, 50 μm L, Immunofluorescence of GBM patient specimens showing LY96+ cells within the SOX2+ tumor cell population. Scale bar, 10 μm. (For interpretation of the ref­ erences to colour in this figure legend, the reader is referred to the Web version of this article.)（图注取自PDF文本层，来源：Cancer Letters, 2026）

Step 2：验证嫌疑犯的"罪行"——LY96对MES GSCs真的重要吗？

锁定之后就是功能验证。他们用两条独立的shRNA在两种MES GSC系（839和2907）里敲低LY96。结果很干脆：增殖变慢、细胞总数减少、神经球形成能力下降。而过表达则反过来，促进生长。更关键的是回补实验——敲低之后再把LY96重新表达，细胞活力就救回来了。@方法论点评：回补实验是验证基因打靶表型特异性的"金标准"，不做的结论说服力大打折扣。

在体内原位成瘤模型里，敲低LY96能显著抑制肿瘤生长，延长荷瘤小鼠生存期。这说明LY96确实是MES GSCs维持生长和干性的"刚需"。

进一步做转录组测序，敲低LY96后MES signature基因集体下调，MES相关的GSEA富集分数显著下降。说明它不只是影响增殖，而是整个MES身份的"骨架"之一。

Fig. 2：LY96 is essential for proliferation and self-renewal of MES GSCs A-B, LY96 mRNA and protein levels measured by qRT-PCR (A) and Western blotting (B) in 839 MES GSCs following knockdown with two independent shRNAs. Data are presented as mean ± SEM from three independent experiments. P < 0.01. C, LY96 protein levels measured by Western blotting in 839 MES GSCs following LY96 overexpression. D–F, Knockdown of LY96 using two independent shRNAs significantly reduced cell viability (D, CellTiter-Glo assay), total cell number (E), and neurosphere for\u00ad mation (F) in MES GSCs compared to shControl. Data are shown as mean ± SD from six independent experiments. P < 0.01, one-way ANOVA with Dunnett’s multiple comparisons test. G, In vitro limiting dilution assay demonstrating reduced sphere-forming frequency in 839 MES GSCs upon LY96 knockdown. P < 0.01. H, Representative images of neurospheres formed by 839 MES GSCs expressing shCont, shLY96-1, or shLY96-2. Scale bar, 100 μm. Images are representative of at least six independent experiments. I, Overexpression of LY96 significantly increased cell growth in 839 MES GSCs compared to vector control (CellTiter-Glo assay). Data are shown as mean ± SD from six independent experiments. P < 0.01. J, LY96 overexpression rescued the reduced viability caused by shRNA-mediated knockdown in MES GSCs (CellTiter-Glo assay). Data are shown as mean ± SD from six independent experiments. P < 0.01. K,L Bioluminescent imaging and quantification of tumor growth in nude mice orthotopically implanted with 839 GSCs transduced with shCont, shLY96-1, or shLY96- 2 (left), and 2907 GSCs transduced with vector or LY96 overexpression (right) at days 7, 14, and 21 post-implantation. M, Kaplan–Meier survival curves of immunodeficient mice implanted intracranially with 839 GSCs expressing shCont or LY96 shRNAs.

Fig. 2. LY96 is essential for proliferation and self-renewal of MES GSCs A-B, LY96 mRNA and protein levels measured by qRT-PCR (A) and Western blotting (B) in 839 MES GSCs following knockdown with two independent shRNAs. Data are presented as mean ± SEM from three independent experiments. P < 0.01. C, LY96 protein levels measured by Western blotting in 839 MES GSCs following LY96 overexpression. D–F, Knockdown of LY96 using two independent shRNAs significantly reduced cell viability (D, CellTiter-Glo assay), total cell number (E), and neurosphere for­ mation (F) in MES GSCs compared to shControl. Data are shown as mean ± SD from six independent experiments. P < 0.01, one-way ANOVA with Dunnett’s multiple comparisons test. G, In vitro limiting dilution assay demonstrating reduced sphere-forming frequency in 839 MES GSCs upon LY96 knockdown. P < 0.01. H, Representative images of neurospheres formed by 839 MES GSCs expressing shCont, shLY96-1, or shLY96-2. Scale bar, 100 μm. Images are representative of at least six independent experiments. I, Overexpression of LY96 significantly increased cell growth in 839 MES GSCs compared to vector control (CellTiter-Glo assay). Data are shown as mean ± SD from six independent experiments. P < 0.01. J, LY96 overexpression rescued the reduced viability caused by shRNA-mediated knockdown in MES GSCs (CellTiter-Glo assay). Data are shown as mean ± SD from six independent experiments. P < 0.01. K,L Bioluminescent imaging and quantification of tumor growth in nude mice orthotopically implanted with 839 GSCs transduced with shCont, shLY96-1, or shLY96- 2 (left), and 2907 GSCs transduced with vector or LY96 overexpression (right) at days 7, 14, and 21 post-implantation. M, Kaplan–Meier survival curves of immunodeficient mice implanted intracranially with 839 GSCs expressing shCont or LY96 shRNAs.（图注取自PDF文本层，来源：Cancer Letters, 2026）

Fig. 3：LY96 maintains MES state of MES GSCs A, Volcano plot showing differentially expressed genes following LY96 knockdown in 839 and 2907 MES GSCs. B, Heatmap displaying changes in GBM subtype signature scores in 839 and 2907 MES GSCs after LY96 knockdown. C, Heatmap illustrating the downregulation of MES marker genes upon LY96 knockdown in both MES GSC lines. D, Gene set enrichment analysis (GSEA) demonstrating reduced enrichment of MES and MES-like gene signatures following LY96 knockdown in 839 and 2907 MES GSCs. Normalized enrichment scores (NES) and P values are shown. E–G, Quantitative RT-PCR analysis of MES marker expression in 839 and 2907 MES GSCs following LY96 knockdown (E), LY96 overexpression (F), or treatment with the LY96 inhibitor L48H37 (1 μM for 48 h; G). Data are presented as mean ± SD from three independent experiments and analyzed by one-way ANOVA. P < 0.05, P < 0.01.

Fig. 3. LY96 maintains MES state of MES GSCs A, Volcano plot showing differentially expressed genes following LY96 knockdown in 839 and 2907 MES GSCs. B, Heatmap displaying changes in GBM subtype signature scores in 839 and 2907 MES GSCs after LY96 knockdown. C, Heatmap illustrating the downregulation of MES marker genes upon LY96 knockdown in both MES GSC lines. D, Gene set enrichment analysis (GSEA) demonstrating reduced enrichment of MES and MES-like gene signatures following LY96 knockdown in 839 and 2907 MES GSCs. Normalized enrichment scores (NES) and P values are shown. E–G, Quantitative RT-PCR analysis of MES marker expression in 839 and 2907 MES GSCs following LY96 knockdown (E), LY96 overexpression (F), or treatment with the LY96 inhibitor L48H37 (1 μM for 48 h; G). Data are presented as mean ± SD from three independent experiments and analyzed by one-way ANOVA. P < 0.05, P < 0.01.（图注取自PDF文本层，来源：Cancer Letters, 2026）

Step 3：挖出通路——LY96是通过哪条路干活的？

他们用敲低后的RNA-seq跑GSEA，发现被影响最显著的通路是NF-κB信号。接着在蛋白水平上验证：敲低LY96后，NF-κB通路关键的磷酸化事件（p-IκBα和p-p65）都被明显削弱了。

更有意思的是，用重组LY96蛋白去刺激细胞，NF-κB磷酸化水平会快速、剂量依赖地上升。而用NF-κB抑制剂PDTC处理，能显著削弱LY96促MES标志基因表达和促增殖的效应。@方法论点评：这里用的是"抑制剂阻断"策略来证明NF-κB是LY96下游关键执行者。科学逻辑是：如果A（LY96）通过B（NF-κB）起作用，那么阻断B后，A的效应应该消失或减弱。这叫"信号轴因果验证"。

Fig. 4：LY96 regulates NF-κB signaling in MES GSCs A–B, Gene set enrichment analysis (GSEA) of transcriptomic data following LY96 knockdown in 839 (A) and 2907 (B) MES GSCs revealed NF-κB signaling as the top downregulated pathway. Normalized enrichment scores (NES) and P values are shown in the heatmaps. C, GSEA of genes positively correlated with LY96 expression in the TCGA GBM dataset identified NF-κB signaling as a significantly enriched pathway. D, NF-κB signaling shows strong positive correlation with the MES signature across TCGA, Rembrandt, Gravendeel, and CGGA datasets. E, Western blot analysis of 839 and 2907 MES GSCs shows reduced levels of phosphorylated IκBα (p-IκBα) and phosphorylated p65 (p-p65) following LY96 knockdown. F, Recombinant LY96 protein (rLY96, 400 ng/mL) partially restored the levels of p-IκBα and p-p65 in LY96-depleted GSCs. G, Dose-dependent activation of NF-κB signaling in MES GSCs following 15-min treatment with increasing concentrations of rLY96 (100–400 ng/mL). H, Time-course analysis of NF-κB activation in MES GSCs treated with rLY96 (400 ng/mL) for 10, 20, 30, and 40 min, showing progressive increases in p-IκBα and p- p65 protein levels. I, qRT-PCR analysis of MES marker genes (CD44, VIM, AGT, RAC2, SLC1A3) in MES GSCs treated with rLY96, PDTC, and PDTC + rLY96. Data are presented as mean ± SD from three independent experiments. P < 0.01. J, Cell viability of 2907 MES GSCs treated with vehicle control, recombinant LY96 (rLY96), NF-κB inhibitor PDTC, or combination of rLY96 and PDTC over 7 days. Cell viability was measured using CellTiter-Glo assay. Data are shown as mean ± SD from six independent experiments. P < 0.01.

Fig. 4. LY96 regulates NF-κB signaling in MES GSCs A–B, Gene set enrichment analysis (GSEA) of transcriptomic data following LY96 knockdown in 839 (A) and 2907 (B) MES GSCs revealed NF-κB signaling as the top downregulated pathway. Normalized enrichment scores (NES) and P values are shown in the heatmaps. C, GSEA of genes positively correlated with LY96 expression in the TCGA GBM dataset identified NF-κB signaling as a significantly enriched pathway. D, NF-κB signaling shows strong positive correlation with the MES signature across TCGA, Rembrandt, Gravendeel, and CGGA datasets. E, Western blot analysis of 839 and 2907 MES GSCs shows reduced levels of phosphorylated IκBα (p-IκBα) and phosphorylated p65 (p-p65) following LY96 knockdown. F, Recombinant LY96 protein (rLY96, 400 ng/mL) partially restored the levels of p-IκBα and p-p65 in LY96-depleted GSCs. G, Dose-dependent activation of NF-κB signaling in MES GSCs following 15-min treatment with increasing concentrations of rLY96 (100–400 ng/mL). H, Time-course analysis of NF-κB activation in MES GSCs treated with rLY96 (400 ng/mL) for 10, 20, 30, and 40 min, showing progressive increases in p-IκBα and p- p65 protein levels. I, qRT-PCR analysis of MES marker genes (CD44, VIM, AGT, RAC2, SLC1A3) in MES GSCs treated with rLY96, PDTC, and PDTC + rLY96. Data are presented as mean ± SD from three independent experiments. P < 0.01. J, Cell viability of 2907 MES GSCs treated with vehicle control, recombinant LY96 (rLY96), NF-κB inhibitor PDTC, or combination of rLY96 and PDTC over 7 days. Cell viability was measured using CellTiter-Glo assay. Data are shown as mean ± SD from six independent experiments. P < 0.01.（图注取自PDF文本层，来源：Cancer Letters, 2026）

Step 4：谁在接LY96的信号？——找到受体TNFRSF1B

LY96是个分泌蛋白，要起作用，得先跟某个受体结合。于是他们做了一个系统性受体筛选，条件是：在MES GSCs和GBM组织里高表达、与MES signature正相关、与患者预后负相关。候选名单上有TNFRSF1B和CD44等。

接下来用免疫共沉淀（Co-IP）联合质谱（LC-MS/MS）来验证物理结合。最终确认TNFRSF1B是LY96的直接结合受体，而CD44没有结合。@方法论点评：“多候选→Co-IP验证→质谱确证"是受体鉴定的经典路线，特别强调"直接相互作用"而不是"表达相关”。

敲低TNFRSF1B后，LY96诱导的NF-κB活化就消失了，细胞增殖促进效应也随之消失。@方法论点评：这里用"受体敲除阻断配体效应"来强化信号轴的因果关系，比单纯的相关性研究高了一个等级。

Fig. 5：The LY96–TNFRSF1B axis regulates NF-κB activation and maintains MES identity in GSCs A, Schematic of the screening strategy to identify candidate receptors of LY96 in MES GSCs. B, Representative peptides of TNFRSF1B were identified from immunoprecipitation (IP) mass spectrometry. C, TNFRSF1B mRNA expression across GBM subtypes—proneural (PN), classical (CL), and mesenchymal (MES)—in the TCGA, Rembrandt, Gravendeel, and CGGA datasets. D, TNFRSF1B mRNA expression in different GSC subtypes (PN, CL, MES) and non-malignant neural stem cells (NSCs). E, Bubble plot showing p values and normalized expression levels of TNFRSF1B in different cellular state tumors from GBM scRNA-seq datasets. F, Correlation analysis showing strong positive association between LY96 expression and MES signature across TCGA, Rembrandt, Gravendeel, and CGGA datasets. G, Kaplan–Meier survival analysis from the TCGA GBM cohort demonstrating that high TNFRSF1B expression is associated with poorer overall survival. H–I, Co-immunoprecipitation (Co-IP) analysis showing physical interaction between LY96 and TNFRSF1B in 839 and 2907 MES GSCs. IgG was used as a negative control. J, Confocal immunofluorescence images showing co-localization of LY96 and TNFRSF1B in 839 and 2907 MES GSCs. Scale bar, 10 μm K, Western blot analysis showing that TNFRSF1B knockdown abrogates the rLY96-induced increase in phosphorylated IκBα (p-IκBα) and p65 (p-p65) in MES GSCs. L, Knockdown of TNFRSF1B blocks the rLY96-induced enhancement of MES GSC viability. Data are presented as mean ± SD from six independent experiments. P < 0.01, one-way ANOVA with Dunnett’s multiple comparison test.

Fig. 5. The LY96–TNFRSF1B axis regulates NF-κB activation and maintains MES identity in GSCs A, Schematic of the screening strategy to identify candidate receptors of LY96 in MES GSCs. B, Representative peptides of TNFRSF1B were identified from immunoprecipitation (IP) mass spectrometry. C, TNFRSF1B mRNA expression across GBM subtypes—proneural (PN), classical (CL), and mesenchymal (MES)—in the TCGA, Rembrandt, Gravendeel, and CGGA datasets. D, TNFRSF1B mRNA expression in different GSC subtypes (PN, CL, MES) and non-malignant neural stem cells (NSCs). E, Bubble plot showing p values and normalized expression levels of TNFRSF1B in different cellular state tumors from GBM scRNA-seq datasets. F, Correlation analysis showing strong positive association between LY96 expression and MES signature across TCGA, Rembrandt, Gravendeel, and CGGA datasets. G, Kaplan–Meier survival analysis from the TCGA GBM cohort demonstrating that high TNFRSF1B expression is associated with poorer overall survival. H–I, Co-immunoprecipitation (Co-IP) analysis showing physical interaction between LY96 and TNFRSF1B in 839 and 2907 MES GSCs. IgG was used as a negative control. J, Confocal immunofluorescence images showing co-localization of LY96 and TNFRSF1B in 839 and 2907 MES GSCs. Scale bar, 10 μm K, Western blot analysis showing that TNFRSF1B knockdown abrogates the rLY96-induced increase in phosphorylated IκBα (p-IκBα) and p65 (p-p65) in MES GSCs. L, Knockdown of TNFRSF1B blocks the rLY96-induced enhancement of MES GSC viability. Data are presented as mean ± SD from six independent experiments. P < 0.01, one-way ANOVA with Dunnett’s multiple comparison test.（图注取自PDF文本层，来源：Cancer Letters, 2026）

Step 5：“旁观者"也不放过——LY96如何影响TAMs？

既然LY96是分泌蛋白，那它不能只在家门口（GSC自身）起作用。作者还做了空间转录组学分析，发现LY96、TNFRSF1B与巨噬细胞标志物（CD68、CD163）在空间位置上高度重叠，提示肿瘤细胞分泌的LY96可能确实"够得着"周围的巨噬细胞。

体外Transwell实验表明，MES GSCs的条件培养基能吸引THP-1分化的巨噬细胞，而敲低GSC中的LY96后，这种吸引能力就下降了。反过来，用重组LY96直接处理巨噬细胞，巨噬细胞会高表达MES标志基因（CD44、VIM等），呈现出一种MES样状态。

最后，他们还在患者标本里用免疫荧光同时染SOX2+CD44+肿瘤细胞和IBA1+CD44+巨噬细胞，从原位印证了这种"LY96阳性的肿瘤细胞—MES样巨噬细胞"空间邻接关系。@方法论点评：这个环节最大的亮点是突破了"只看肿瘤细胞"的惯性，把"旁分泌重编程免疫细胞"这个维度拉进来了，为"双重靶向"提供了理论依据。

Fig. 6：LY96 secreted by MES GSCs promotes MES-like reprogramming of TAMs A, Spatial transcriptomic scatter plots showing co-localization of MES-like gene signatures with LY96, TNFRSF1B, CD68, and CD163 expression in GBM tissue sections. B-D, Transwell migration assays showing that LY96 expression influences TAM recruitment. (C–D) THP1-derived TAMs treated with conditioned media from GSCs transduced with shCont or shLY96. (E) TAMs treated with recombinant LY96 (rLY96, 400 ng/mL) for 24 h. Migrated cells were fixed and stained; scale bar, 50 μm E, Immunofluorescent staining of GBM patient specimens showing SOX2+CD44+ tumor cells and IBA1+CD44+ macrophages. Scale bar, 10 μm. F-G, qRT-PCR analysis of MES marker genes (CD44, VIM, AGT, RAC2, SLC1A3) in THP1-derived TAMs: (F) Treated with conditioned media from LY96-knockdown MES GSCs (839 and 2907). (G) Stimulated with recombinant LY96 (400 ng/mL). Data are shown as mean ± SD from three independent experiments and analyzed by one-way ANOVA. P < 0.01.

Fig. 6. LY96 secreted by MES GSCs promotes MES-like reprogramming of TAMs A, Spatial transcriptomic scatter plots showing co-localization of MES-like gene signatures with LY96, TNFRSF1B, CD68, and CD163 expression in GBM tissue sections. B-D, Transwell migration assays showing that LY96 expression influences TAM recruitment. (C–D) THP1-derived TAMs treated with conditioned media from GSCs transduced with shCont or shLY96. (E) TAMs treated with recombinant LY96 (rLY96, 400 ng/mL) for 24 h. Migrated cells were fixed and stained; scale bar, 50 μm E, Immunofluorescent staining of GBM patient specimens showing SOX2+CD44+ tumor cells and IBA1+CD44+ macrophages. Scale bar, 10 μm. F-G, qRT-PCR analysis of MES marker genes (CD44, VIM, AGT, RAC2, SLC1A3) in THP1-derived TAMs: (F) Treated with conditioned media from LY96-knockdown MES GSCs (839 and 2907). (G) Stimulated with recombinant LY96 (400 ng/mL). Data are shown as mean ± SD from three independent experiments and analyzed by one-way ANOVA. P < 0.01.（图注取自PDF文本层，来源：Cancer Letters, 2026）

Step 6：能不能打掉它？——小分子抑制剂L48H37的效果

最后他们拿出了一个小分子抑制剂L48H37，这是一个已报道的LY96靶向药。体外IC50测试显示，MES亚型的GSCs对L48H37更敏感（相比经典型和前神经型）。处理L48H37后，NF-κB磷酸化水平下降，MES标志基因下调。药代动力学实验证明它能通过血脑屏障。体内给药能显著抑制原位瘤生长，延长生存期，并且瘤内MES样TAMs的比例也下降了。

@方法论点评：从"表型→分子→通路→受体→微环境→药物干预”，这个逻辑闭环相当完整，既有基础机制，又有转化验证，符合肿瘤生物学研究的"完整证据链"标准。

Fig. 7：Pharmacologic targeting of LY96 suppresses GSC growth in vitro and in vivo A, Determination of the half-maximal inhibitory concentration (IC50) of L48H37 across GSC subtypes: mesenchymal (MES; 839, 2907), classical (CL; 3028, RKI), and proneural (PN; 3094, MGG8). B, qRT-PCR analysis demonstrates that L48H37 inhibition in 839 and 2907 MES GSCs leads to reduced expression of genes in NF-κB signaling. Data are presented as mean ± SEM from three independent experiments. P < 0.01. C, IB analysis of p-IκBα and p-p65 in MES GSCs treated with different concentrations of L48H37. D, IB analysis of p-IκBα and p-p65 in MES GSCs treated with L48H37 at different time points. E, LC-MS/MS spectrogram(left) and concentrations measured by LC-MS/MS(right) of L48H37 in mouse plasma and brain tissues. p < 0.01, unpaired two-sided Student’s t-test. F, Schematic outlining the experimental design for evaluating the in vivo effects of LY96 inhibition using L48H37 in orthotopic GBM xenograft models. G,H, Representative bioluminescence images and quantification showing tumor progression in nude mice bearing intracranial xenografts of 839 (top) or 2907 (bottom) GSCs treated with vehicle (DMSO) or L48H37. Images were captured on days 7, 14, and 21 post-treatment. Scale bar reflects bioluminescent intensity. I, Kaplan–Meier survival curves of immunodeficient mice implanted with 839 or 2907 GSCs and treated with shCont, shLY96-1, or shLY96-2. J, Immunofluorescence analysis of brain sections from mice sacrificed 40 days after implantation with 839 or 2907 GSCs, showing co-localization of DAPI (blue), IBA1 (red), and CD44 (green). Scale bar, 10 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 7. Pharmacologic targeting of LY96 suppresses GSC growth in vitro and in vivo A, Determination of the half-maximal inhibitory concentration (IC50) of L48H37 across GSC subtypes: mesenchymal (MES; 839, 2907), classical (CL; 3028, RKI), and proneural (PN; 3094, MGG8). B, qRT-PCR analysis demonstrates that L48H37 inhibition in 839 and 2907 MES GSCs leads to reduced expression of genes in NF-κB signaling. Data are presented as mean ± SEM from three independent experiments. P < 0.01. C, IB analysis of p-IκBα and p-p65 in MES GSCs treated with different concentrations of L48H37. D, IB analysis of p-IκBα and p-p65 in MES GSCs treated with L48H37 at different time points. E, LC-MS/MS spectrogram(left) and concentrations measured by LC-MS/MS(right) of L48H37 in mouse plasma and brain tissues. p < 0.01, unpaired two-sided Student’s t-test. F, Schematic outlining the experimental design for evaluating the in vivo effects of LY96 inhibition using L48H37 in orthotopic GBM xenograft models. G,H, Representative bioluminescence images and quantification showing tumor progression in nude mice bearing intracranial xenografts of 839 (top) or 2907 (bottom) GSCs treated with vehicle (DMSO) or L48H37. Images were captured on days 7, 14, and 21 post-treatment. Scale bar reflects bioluminescent intensity. I, Kaplan–Meier survival curves of immunodeficient mice implanted with 839 or 2907 GSCs and treated with shCont, shLY96-1, or shLY96-2. J, Immunofluorescence analysis of brain sections from mice sacrificed 40 days after implantation with 839 or 2907 GSCs, showing co-localization of DAPI (blue), IBA1 (red), and CD44 (green). Scale bar, 10 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)（图注取自PDF文本层，来源：Cancer Letters, 2026）

核心结论

本文的核心发现可以概括为一句话：LY96在MES型GBM中是一个关键的枢纽分子。

在MES GSC内部，它通过自分泌方式结合受体TNFRSF1B→激活NF-κB通路→维持GSC增殖、干性和MES转录身份。 在微环境层面，它被GSC分泌出来后，以旁分泌方式作用于TAMs，把巨噬细胞"教育"成MES样状态，构建一个有利于肿瘤进展的免疫微环境。 用L48H37靶向LY96能同时"打击"肿瘤干细胞和重编程的免疫细胞，体内显示出较好的抗肿瘤效果。

这意味着LY96可能是MES型GBM的一个关键的"生态位构建者"，同时控制着"种子"（GSC）和"土壤"（TAM微环境）。

对耐药/DTP/PGCC的启示

自分泌维持机制可能是DTP存活的"后门"：LY96-TNFRSF1B-NF-κB这个自分泌环路是MES GSC自我更新所必需的。在靶向治疗压力下，这类自分泌信号通路往往成为DTP（药物耐受持久细胞）赖以生存的"备用引擎"。未来可以探索在标准治疗基础上联合L48H37，是否能缩小DTP池，延缓复发。 微环境重编程值得纳入耐药模型：多数耐药研究把注意力集中在肿瘤细胞本身。本文提供了一个明确的例子：肿瘤细胞通过分泌一个因子直接教育巨噬细胞，而巨噬细胞反过来又支持肿瘤。这种"肿瘤—免疫"互作环路应该成为耐药模型的重要组成部分，尤其是在研究微环境介导的获得性耐药时。 MES状态与PGCC的可能交集：NF-κB通路的持续激活在多倍体巨细胞（PGCC）的形成和复苏中也常有报道。LY96是否参与了PGCC的生成或维持，文中未讨论，但这是一个值得跟进的方向——特别是MES GBM对化疗耐药的背景下，LY96可能通过NF-κB连接"干细胞性"“免疫抑制"和"多倍体巨细胞介导的复苏"这三者。

局限

主要的体内模型用的是免疫缺陷鼠（裸鼠），无法全面评估LY96对适应性免疫系统的影响，尤其无法区分LY96对T细胞等其他免疫细胞亚群的作用。 关于LY96如何从GSC中分泌、以及LY96-TNFRSF1B结合的亲和力、结合后的构象变化等结构生物学信息，文中未涉及。 L48H37虽然能透过血脑屏障，但该化合物的临床前毒理学数据、治疗窗口、长期给药方案，本文并未深入探讨。 MES样TAMs的功能性表征还可以做得更细，比如它们是否确实具有更强的促血管生成或免疫抑制功能，文中更多停留在转录特征层面。

来源

期刊：Cancer Letters，2026。DOI: 10.1016/j.canlet.2026.218409